interpack 2014: 21st century pharma packaging

WHEN the medicinal products market was still dominated by blockbuster medicines, the pharmaceutical companies had it easy: they developed active substances that could be used to treat a large number of patients and produced medicines against widespread ailments such as high blood pressure and diabetes by the millions in standardised mass processes. The big multinationals thus earned billions year after year. 

But times are changing, and the growth of biopharmaceuticals is just one indication of the changes the industry is undergoing. 

Visiogain, the British market research company, confirms this trend. According to its findings, annual sales of biopharmaceuticals are currently experiencing double-digit growth and a continuing rise is forecast for the coming ten years. This is forcing pharmaceutical companies to adapt. Some biomolecules readily decompose, while others are highly aggressive and attack the surfaces of primary packages. Containers with improved barrier properties and enhanced impact resistance are therefore required in order to reliably protect precious biosubstances. More flexible production processes are also called for, capable of precisely dosing even the tiniest quantities of active substance. 
At the same time, pharmaceuticals manufacturers have to safeguard their medicines better against falsification. According to studies by the World Health Organisation, the falsification rate among medicines sold via dubious websites is already 50 per cent.  Read more about pharmaceutical packaging at interpackZapatillas y ropa deportiva para ni?o